B+
Bull case
25%
Probability
Target price
$110.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
MDT
MedtronicCNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$99.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$74.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-30
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+57.5
Score
AI commentary
Company-source tone is positive after the Q1 guidance raise and Hugo instrument clearance, while the dated MiniMed exchange offer is a nearer-term event. Recent packet headlines provide little MDT-specific corroboration. Social, options, short-interest and employee metrics are unavailable; zeros are placeholders, not neutral observations. No verified post-earnings analyst revisions or reliable immediate price-reaction attribution were supplied.
RankAlpha Sentiment Codex - 2026-09-30
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-09eventMiniMed exchange-offer deadlineMedium impact
Medtronic's offer to exchange MiniMed shares for Medtronic shares is scheduled to expire October 9 unless extended or terminated. Completion and the final exchange ratio could change the share count and the market's view of the remaining portfolio; neither outcome is assured. [#8-K-2026-09-17] Medtronic's SEC-filed announcement
2027-06-30catalystTest of raised FY2027 guidance without an extra-week boostMedium impact
Q1 revenue was $9.756 billion and non-GAAP EPS was $1.45. Medtronic raised FY2027 organic revenue-growth guidance to 7.25%-7.75% and non-GAAP EPS guidance to $5.94-$6.00, but estimates the extra fiscal week benefited Q1 organic growth by about $570 million. Subsequent results must demonstrate durable growth and margin conversion. [#SEC-8K-2026-09-01] Medtronic earnings release
2027-06-30catalystHugo instrument adoption and cardiovascular growthMedium impact
September's FDA clearance expanded the U.S. Hugo instrument set with LigaSure RAS Maryland, while Q1 Cardiac Ablation Solutions grew 88% organically. Hospital utilization of Hugo and sustained ablation growth are the operating tests; the clearance alone does not establish material revenue. Medtronic Hugo release [#SEC-8K-2026-09-01]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-30 • Updated nightlySource: Internal modelMethodology